These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 6699662)

  • 1. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.
    Ewer MS; Ali MK; Mackay B; Wallace S; Valdivieso M; Legha SS; Benjamin RS; Haynie TP
    J Clin Oncol; 1984 Feb; 2(2):112-7. PubMed ID: 6699662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity.
    Druck MN; Gulenchyn KY; Evans WK; Gotlieb A; Srigley JR; Bar-Shlomo BZ; Feiglin DH; McEwan P; Silver MD; Millband L
    Cancer; 1984 Apr; 53(8):1667-74. PubMed ID: 6697304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy.
    Mason JW; Bristow MR; Billingham ME; Daniels JR
    Cancer Treat Rep; 1978 Jun; 62(6):857-64. PubMed ID: 667859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gated blood pool scintigraphic monitoring of doxorubicin cardiomyopathy: comparison of camera and computerized probe results in 101 patients.
    Strashun AM; Goldsmith SJ; Horowitz SF
    J Am Coll Cardiol; 1986 Nov; 8(5):1082-7. PubMed ID: 3760382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of noninvasive cardiac parameters in the detection and evaluation of adriamycin cardiotoxicity.
    Shuman RD; Ettinger DS; Abeloff MD; Livengood SV; Fortuin NJ
    Johns Hopkins Med J; 1981 Aug; 149(2):57-63. PubMed ID: 7253365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adriamycin (doxorubicin) cardiotoxicity: a review.
    Chlebowski RT
    West J Med; 1979 Nov; 131(5):364-8. PubMed ID: 394479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline cardiomyopathy monitored by morphologic changes.
    Billingham ME; Mason JW; Bristow MR; Daniels JR
    Cancer Treat Rep; 1978 Jun; 62(6):865-72. PubMed ID: 667860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serial determination of anthracycline poisoning in children].
    Stein JI; Langevin A; Benson LN; Souza MD; Wilson G; Chan H
    Wien Klin Wochenschr; 1989 Jan; 101(1):45-8. PubMed ID: 2913725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.
    McKillop JH; Bristow MR; Goris ML; Billingham ME; Bockemuehl K
    Am Heart J; 1983 Nov; 106(5 Pt 1):1048-56. PubMed ID: 6637763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radionuclide ventriculography detects early anthracycline cardiotoxicity in children with Hodgkin lymphoma.
    Tantawy AA; Elmasry OA; Shaaban M; Toaima DN; El Shahat AM
    J Pediatr Hematol Oncol; 2011 May; 33(4):e132-7. PubMed ID: 21516011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of left ventricular function using radionuclide scans in patients receiving mitoxantrone.
    Aapro MS; Alberts DS; Woolfenden JM; Mackel C
    Invest New Drugs; 1983; 1(4):341-7. PubMed ID: 6678882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
    J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiac risks of adriamycin. Early detection of high-risk patients by isotopic cardiac function study].
    Pecking A; Delorme G; Berlie J; Goupil A; Tubiana M; Turpin F; Meeus L; Clavel B
    Presse Med; 1983 Nov; 12(39):2445-8. PubMed ID: 6227889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the cardiotoxicity of the anthracyclines.
    Carlson RW
    Oncology (Williston Park); 1992 Jun; 6(6):95-100, 104, 107, discussion 107-8. PubMed ID: 1535212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Endomyocardial biopsy as a method of surveilling adriamycin cardiac toxicity. 28 biopsies in 26 patients].
    Bouhour JB; Petitier H; Delajartre AY; Fumoleau P; Rozo L; Nicolas G
    Arch Mal Coeur Vaiss; 1983 Nov; 76(11):1277-83. PubMed ID: 6419695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac evaluation of mitoxantrone.
    Unverferth DV; Unverferth BJ; Balcerzak SP; Bashore TA; Neidhart JA
    Cancer Treat Rep; 1983 Apr; 67(4):343-50. PubMed ID: 6850653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac toxicity of adriamycin-DNA complex and rubidazone: evaluation by electrocardiogram and endomyocardial biopsy.
    Benjamin RS; Mason JW; Billingham ME
    Cancer Treat Rep; 1978 Jun; 62(6):935-9. PubMed ID: 667871
    [No Abstract]   [Full Text] [Related]  

  • 19. Time- and dose-dependent changes in ejection fraction after anthracycline therapy.
    Narahara KA; Singer JW; Ritchie JL; Williams DL; Hamilton GW; Kennedy JW
    J Cardiovasc Pharmacol; 1979; 1(4):395-401. PubMed ID: 94617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update.
    Benjamin RS; Chawla SP; Ewer MS; Carrasco CH; Mackay B; Holmes F
    Invest New Drugs; 1985; 3(2):117-21. PubMed ID: 4019116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.